Achieving Low-Density Lipoprotein Cholesterol Goals in High-Risk Patients in Managed Care: Comparison of Rosuvastatin, Atorvastatin, and Simvastatin in the SOLAR Trial

Insull Jr., William; Ghali, Jalal K.; Hassman, David R.; Yčas, Joseph W.; Gandhi, Sanjay K.; Miller, Elinor
May 2007
Mayo Clinic Proceedings;May2007, Vol. 82 Issue 5, p543
Academic Journal
OBJECTIVE: To evaluate attainment of the National Cholesterol Education Program (NCEP) Adult Treatment Panel (ATP) III low-density lipoprotein cholesterol (LDL-C) goal of less than 100 mg/dL with statin treatments in managed care patients at high risk for coronary heart disease. PATIENTS AND METHODS: In a randomized, open-label, multicenter trial (SOLAR [Satisfying Optimal LDL-C ATP III goals with Rosuvastatin]) performed at 145 US clinical centers from June 5, 2002 to July 12, 2004, high-risk men and women in a managed care population received typical starting doses of rosuvastatin (10 mg/d), atorvastatin (10 mg/d), or simvastatin (20 mg/d) for 6 weeks. Those who did not meet the LDL-C target of less than 100 mg/dL at 6 weeks had their dose titrated (doubled), and all patients were followed up for another 6 weeks. RESULTS: A total of 1632 patients were randomized to 1 of the 3 treatment regimens. After 6 weeks, 65% of patients taking rosuvastatin reached the LDL-C target of less than 100 mg/dL vs 41% with atorvastatin and 39% with simvastatin (P<.001 vs rosuvastatin for both). After 12 weeks, 76% of patients taking rosuvastatin reached the LDL-C target of less than 100 mg/dL vs 58% with atorvastatin and 53% with simvastatin (P<.001 vs rosuvastatin for both). Reductions in the LDL-C level, total cholesterol level, non-high-density lipoprotein cholesterol (non-HDL-C) level, and non-HDL-C/HDL-C ratio were significantly greater with rosuvastatin at both 6 and 12 weeks compared with the other statins. Adverse events were similar in type and frequency in all treatment groups, and only 3% of all patients discontinued treatment because of adverse events. No myopathy was observed, no clinically important impact on renal function was attributed to study medications, and clinically important increases in serum transaminases were rare. CONCLUSION: In a managed care population, 10 mg of rosuvastatin treatment resulted in more patients reaching the NCEP ATP III LDL-C goal compared with 10 mg of atorvastatln and 20 mg of simvastatin, potentially reducing the need for titration visits.


Related Articles

  • NCEP Issues Interim Guidelines on Management of Cholesterol. Neff, Matthew J. // American Family Physician;10/15/2004, Vol. 70 Issue 8, p1591 

    Deals with an interim guidelines issued by the U.S. National Cholesterol Education Program as an addendum to the Adult Treatment Panel III guidelines regarding the management of cholesterol. Information on the five major clinical trials of statin therapy with clinical end points that have been...

  • A Multicenter, Placebo-Controlled, Dose-Ranging Study of Atorvastatin. Schrott, Helmut; Fereshetian, Anita Gmerek; Knopp, Robert H.; Bays, Harold; Jones, Peter H.; Littlejohn, Thomas W.; McLain, Richard; Black, Donald M. // Journal of Cardiovascular Pharmacology & Therapeutics;Jun1998, Vol. 3 Issue 2, p119 

    The article presents a study that assesses the safety and dose-related effects of atorvastatin calcium in patients with coronary heart disease. Results showed that atorvastatin is effective in lowering plasma low-density lipoprotein (LDL) cholesterol, triglycerides, and apoB levels in a...

  • Lower incidence of CHD, other vascular events observed with absolute reductions in LDL-C.  // Formulary;Jan2006, Vol. 41 Issue 1, p35 

    The article reports that absolute reductions in low density lipoproteins-C reduce the incidence of coronary heart disease and other major vascular events through statin therapy. The prospective meta-analysis of data was largely irrespective of the initial lipid profile. There were corresponding...

  • ATP III incorporates recent findings. L. M. P. // Pharmacy Today;Sep2004, Vol. 10 Issue 9, p8 

    The article reports the target low-density lipoprotein cholesterol levels of 70 mg/dL are supported for high-risk patients in a summer update to the 2001 guidelines of the Adult Treatment Panel III of the National Cholesterol Education Program (NCEP). The added recommendations, developed by a...

  • The 2004 Controversy Over U.S. Statin-Treatment Guidelines.  // HealthFacts;Jul2006, Vol. 31 Issue 7, p3 

    Deals with the controversy raised by the statin-treatment guidelines issued by the U.S. National Cholesterol Education Program on July 12, 2004. Overview of the updated statin-treatment guidelines; Conflicts of interest issue surrounding the new guidelines; Objections to the expanded guidelines.

  • New LDL guidelines bode well for statins.  // Medical Marketing & Media;Aug2004, Vol. 39 Issue 8, p11 

    Reports on the issuance of the National Cholesterol Education Program on new guidelines that call for people at high and moderate risk for heart attacks. Suggestion of the guidelines that people should lower their LDL cholesterol by 30 to 40 percent to a certain level; Content of guidelines on...

  • LDL-cholesterol lowering effect of a generic product of simvastatin compared to simvastatin (Zocor) in Thai hypercholesterolemic subjects - a randomized crossover study, the first report from Thailand. Wiwanitkit, Viroj; Wangsaturaka, Danai; Tangphao, Oranee // BMC Clinical Pharmacology;2002, Vol. 2, p1 

    Background: It is commonly agreed that people with a high blood LDL-cholesterol will have a higher risk of coronary artery disease (CAD) than people with low blood LDL-cholesterol. Due to the increasingly high costs of medication in Thailand, the government has set up several measures to combat...

  • Treating to Meeting NCEP-Recommended LDL Cholesterol Concentrations with Atorvastatin, Fluvastatin, Lovastatin, or Simvastatin in Patients with Risk Factors for Coronary Heart Disease. Hunninghake, Donald; Bakker-Arkema, Rebecca G.; Wigand, James P.; Drehobl, Margaret; Schrott, Helmut; Early, James L.; Abdallah, Paul; McBride, Scott; Black, Donald M. // Journal of Family Practice;Nov1998, Vol. 47 Issue 5, p349 

    BACKGROUND. Our study compared use of atorvastatin, fluvastatin, lovastatin, and simvastatin for lowering low-density lipoprotein (LDL) cholesterol concentration in patients at risk for coronary heart disease (CHD). The goal was to reach the LDL cholesterol levels recommended by the National...

  • Treating dyslipidemia in the high-risk patient. Jones, Peter H. // Journal of Family Practice; 

    The article discusses the use of low-density lipoproteins (LDL) in reducing dyslipidemia which contributes to coronary heart disease (CHD). The U.S. National Cholesterol Education Program has provided guidelines on the reduction of serum levels for primary and secondary prevention of CHD with...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics